Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CBLB102
Quinacrine · 1 trial · 1 indication
Patients who achieved a complete response (CR) or a partial response (PR) to therapy were allowed to continue to receive treatment until disease progression or unacceptable toxicity occurred, until the patient discontinued treatment for another reason, or for a total of 6 months. Patients who continued to show a CR or PR or who maintained stable disease (SD) after 6 months of therapy were to be allowed to continue therapy at the investigator's discretion.
| Arm | Type | Description |
|---|---|---|
| Quinacrine | EXPERIMENTAL | Uncontrolled treatment arm |
| Name | Type | Description |
|---|---|---|
| Quinacrine | DRUG | 100 mg daily |
Inclusion Criteria: * Patients must be males, at least 18 years of age, with pathologically confirmed adenocarcinoma of the prostate * Patients must have evidence of androgen-independent metastatic prostate cancer (AIMPC) following standard antiandrogen withdrawal. AIMPC will be defined as the cate...
Quinacrine has been studied as a treatment for androgen-independent prostate cancer, also called hormone-refractory prostate cancer. It was evaluated in a Phase 2 trial in men whose disease had progressed despite androgen deprivation therapy. Quinacrine is not an approved therapy for prostate cancer and remains investigational in this setting.
Community Health Systems, Inc., which trades under the ticker CYH, is listed as the developer of Quinacrine for prostatic cancer. The company sponsored the Phase 2 study of the drug in patients with androgen-independent prostate cancer.
Quinacrine is in Phase 2 development for prostatic cancer. One Phase 2 trial has been conducted, and it is now completed. The drug is investigational for this indication and has not been approved by the FDA for treating prostate cancer.
Quinacrine was evaluated in the Phase 2 trial NCT00417274, titled Quinacrine Treatment in Patients With Androgen-Independent Prostate Cancer. The completed study enrolled 31 men aged 18 years and older. It was an uncontrolled trial without randomization or double-blinding, and it did not select patients by biomarker.
No. Quinacrine has not been approved for prostate cancer and is an investigational agent in this indication. Its only recorded study in prostatic cancer is a completed Phase 2 trial, so it remains in clinical development rather than being an available treatment option for patients.